He is also the District Chief of Ophthalmology of Capital Health in Halifax, Nova Scotia.

Doctor Cruess’ main research interest is in new therapies for age-related macular degeneration (AMD) and diabetic retinopathy.

He is actively involved in several clinical trials investigating diabetic macular edema, choroidal neovascularization secondary to AMD, and verteporfin photodynamic therapy (PDT) versus ranibizumab monotherapy.

Dr Cruess is a member of the Canadian Medical Association, the Macula Society, the Retina Society, and Club Jules Gonin.

He is also a Fellow of the Royal College of Physicians and Surgeons of Canada and the American Academy of Ophthalmology (AAO).

He is currently Past President of the Canadian Ophthalmological Society and serves on the Board of Directors of the Pan-American Association of Ophthalmology.

He has recently published in journals including Pharmacoeconomics, Acta Ophthalmologica, and Canadian Journal of Ophthalmology.